1. Clinical perspective on the use of human amniotic epithelial cells to treat congenital metabolic diseases with a focus on maple syrup urine disease
- Author
-
Satoshi Hayakawa, Brendan H. Grubbs, Toshio Miki, Chika Takano, Mika Ishige, Ichiro Morioka, and Erika Ogawa
- Subjects
0301 basic medicine ,Medicine (General) ,placenta ,medicine.medical_treatment ,Economic shortage ,Liver transplantation ,Bioinformatics ,Regenerative medicine ,stem cell transplantation ,Cell therapy ,03 medical and health sciences ,0302 clinical medicine ,R5-920 ,Maple Syrup Urine Disease ,Pregnancy ,medicine ,Humans ,Amnion ,cell transplantation ,liver regeneration ,QH573-671 ,business.industry ,Maple syrup urine disease ,Epithelial Cells ,Cell Biology ,General Medicine ,cellular therapy ,medicine.disease ,Liver regeneration ,030104 developmental biology ,Amniotic epithelial cells ,Female ,Stem cell ,business ,Cytology ,030217 neurology & neurosurgery ,Perspectives ,Developmental Biology - Abstract
Congenital metabolic diseases are a group of hereditary disorders caused by the deficiency of a single specific enzyme activity. Without appropriate therapy, affected patients suffer severe neurologic disability and eventual death. The current mainstays of management attempt to slow disease progression, but are not curative. Several of these diseases have demonstrated significant benefits from liver transplantation; however, this approach is limited by the morbidity associated with this invasive procedure and a shortage of donor organs. Therefore, there is a need to establish a new strategy for improving the quality of a life for these patients. One potential solution is regenerative therapy using hepatocytes generated from stem cells. Herein, we discuss pertinent issues necessary for clinical application of the human amniotic epithelial cell, a type of placental stem cell. Focusing on maple syrup urine disease as an example, where liver replacement is an effective therapy, we explore this approach from a clinician's perspective., Human amniotic epithelial cell (hAEC) transplantation therapy has therapeutic potential for the treatment of congenital metabolic diseases including maple syrup urine disease. hAECs isolated from the placenta can be transplanted by injection into the portal vein system. In this perspective article, we outline practical considerations for hAEC transplantation, which should help to design further studies toward clinical application.
- Published
- 2021